JAK2 and myeloproliferative disorder: Crucially, the thrombotic risk in PV and ET is far beyond that observed in secondary polycythemia or thrombocythemia, indicating that intrinsic factors over and above the increase in erythrocytes and platelets and in blood viscosity drive the thrombotic risk in JAK2-V617F MPN.